cSCC remains a disease with a significant need for more effective and tolerable treatment options, particularly for patients with concomitant hematological malignancies, solid organ transplant ...
Arvinas, Pfizer announce initial phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combo with abemaciclib at 2024 SABC symposium: New Haven, Connecticut Thursday, Dec ...
The standard first-line treatment for advanced ER+/HER2- breast cancer combines endocrine therapy with CDK4/6 inhibitors ... Meanwhile, everolimus has shown efficacy in inhibiting other resistance ...